Last reviewed · How we verify
MK-1045
At a glance
| Generic name | MK-1045 |
|---|---|
| Also known as | CN201 |
| Sponsor | MSD R&D (China) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) (PHASE1)
- A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004) (PHASE1)
- A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK-1045 CI brief — competitive landscape report
- MK-1045 updates RSS · CI watch RSS
- MSD R&D (China) Co., Ltd. portfolio CI